TC Biopharm (Holdings) Price, Forecast, Insider, Ratings, Fundamentals & Signals

Edinburgh, scotland , april 4, 2024 /prnewswire/ -- tc biopharm (holdings) plc ("tc biopharm" or the "company") (nasdaq: tcbp) a clinical stage biotechnology company developing platform allogeneic gamma-delta t cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent as part of its m&a strategy aimed at expanding its therapeutic platform and leveraging nk (natural killer) cells in treating both solid tumors and other indications. the target asset acquisition covers the proprietary manufacturing process of two allogeneic car-nk therapeutics, both of which tcb believes are valuable as monotherapies as well as in conjunction with tcb-008 in the future.

Developing streamlined approach to reduce cost per patient by 85% edinburgh, scotland , april 2, 2024 /prnewswire/ -- tc biopharm (holdings) plc ("tc biopharm" or the "company") (nasdaq: tcbp) a clinical stage biotechnology company developing platform allogeneic gamma-delta t cell therapies for cancer and other indications, today announced that it is developing a streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000.  this undertaking, which will utilize its current infrastructure, will provide a cost reduction of 85% per patient treatment.

Edinburgh, scotland , march 19, 2024 /prnewswire/ -- tc biopharm (holdings) plc ("tc biopharm" or the "company") (nasdaq: tcbp) a clinical stage biotechnology company developing platform allogeneic gamma-delta t cell therapies for cancer and other indications, today announced that it has adjourned its general meeting of the company to a later date.  tc biopharm is awaiting clarity on additional information of a material matter related to the shareholder vote.

•  company receives gross proceeds of $1.26 m from transaction edinburgh, scotland , march 18, 2024 /prnewswire/ -- tc biopharm (holdings) plc ("tc biopharm" or the "company") (nasdaq: tcbp) a clinical stage biotechnology company developing platform allogeneic gamma-delta t cell therapies for cancer and other indications, today announced that an institutional investor has exercised cash only warrants represented 623,750 american depository shares (ads) at an exercise price of $2.02. the gross proceeds of the warrant exercise was $1,263,000 with a net cash infusion of $1,168,275 to the company post fees associated with the exercise to hc wainwright & co. there was no additional consideration or inducement paid for the exercise of the series d warrants in this transaction.

Edinburgh, scotland , march 1, 2024 /prnewswire/ -- tc biopharm (holdings) plc ("tc biopharm" or the "company") (nasdaq: tcbp) a clinical stage biotechnology company developing platform allogeneic gamma-delta t cell therapies for cancer and other indications, today announced that chief executive officer, bryan kobel was again featured on a live interview on "the big biz show," an emmy award-winning nationally syndicated tv and radio show.   bryan kobel, ceo stated, "it was great to reconnect with 'sully' and his crew in order to provide an update on all the exciting developments that are going on at tc biopharm.

The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.

EDINBURGH, Scotland , Aug. 29, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, September 11 th through Wednesday, September 13 th starting at 7:00 a.m.

Why would anyone want to buy penny stocks? They're extremely risky.

Most traders dream of hitting it big, and penny stocks are some of the most attractive for day traders. It can be any given session where we see at least a handful of cheap stocks under $5 explode.

EDINBURGH, Scotland, April 19, 2023 (GLOBE NEWSWIRE) -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, is proud to announce its participation at the upcoming Sequire Investor Summit. This highly anticipated event, scheduled for April 24-26, 2023 at La Concha Resort in San Juan, Puerto Rico, promises to offer an array of exciting opportunities for funds, companies, and investors.

The FDA has granted Orphan Drug designation to TC Biopharm Ltd's (NASDAQ: TCBP) lead product OmnImmune for use in Acute Myeloid Leukemia.  After reviewing the Phase 1b/2a trial results in relapsed/refractory AML patients, the FDA approved the Company's application.

Here's what you need to know about trading penny stocks on March 9th The post Trading Penny Stocks? Top Stock Market News for March 9th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here's three penny stocks that investors are watching rig The post Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February   appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The Arena Group, a media holding company operating Sports Illustrated, TheStreet, and other brands, raised $30 million at a $172 million market cap. Nine SPACs went public this past week.

5 must watch penny stocks that you should know about in February The post 5 ‘Must Watch' Penny Stocks For February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.